Deregulated Akt3 activity promotes development of malignant melanoma

Cancer Research

Volumn 64, Issue 19, 2004, Pages 7002-7010

  Stahl, Jill M ^a   Sharma, Arati ^a   Cheung, Mitchell ^a   Zimmerman, Melissa ^a   Cheng, Jin Q ^b   Bosenberg, Marcus W ^c   Kester, Mark ^a   Sandirasegarane, Lakshman ^a   Robertson, Gavin P ^a,d  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c UNIVERSITY OF VERMONT   (United States)

^d Foreman Foundation for Melanoma Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN KINASE B ALPHA; PROTEIN KINASE B BETA; PROTEIN KINASE B GAMMA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENE LOSS; HUMAN; HUMAN CELL; MELANOMA; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SKIN CARCINOGENESIS; TUMOR GROWTH;

ANIMALS; APOPTOSIS; DISEASE PROGRESSION; ENZYME ACTIVATION; FEMALE; HUMANS; MELANOMA; MICE; MICE, NUDE; ONCOGENE PROTEINS; PHOSPHORIC MONOESTER HYDROLASES; PROTEIN ISOFORMS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; RNA, SMALL INTERFERING; SKIN NEOPLASMS; TUMOR SUPPRESSOR PROTEINS;

EID: 4944249733     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-1399     Document Type: Article

References (41)

1. Schalick WO, Albino AP, Reed JA, et al. Melanoma. In: Miller SJ, Maloney ME, editors. Cutaneous oncology: pathophysiology, diagnosis and management. Malden, MA: Blackwell Science Inc.; 1998. p. 180-348.
2. Jemal A, Devesa SS, Hartge P, Tucker MA. Recent trends in cutaneous melanoma incidence among whites in the United States. J Natl Cancer Inst (Bethesda) 2001;93:678-83.
3. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics. CA Cancer J Clin 2002;52:23-47.
4. Soengas MS, Lowe SW. Apoptosis and melanoma chemoresistance. Oncogene 2003; 22:3138-51.
5. Serrone L, Hersey P. The chemoresistance of human malignant melanoma: an update. Melanoma Res 1999;9:51-8.
6. Grossman D, Altieri DC. Drug resistance in melanoma: mechanisms, apoptosis, and new potential therapeutic targets. Cancer Metastasis Rev 2001;20:3-11.
7. Helmbach H, Rossmann E, Kern MA, Schadendorf D. Drug-resistance in human melanoma. Int J Cancer 2001;93:617-22.
8. Ballo MT, Ang KK. Radiation therapy for malignant melanoma. Surg Clin N Am 2003;83:323-42.
9. Hersey P. Adjuvant therapy for high-risk primary and resected metastatic melanoma. Intern Med J 2003;33:33-43.
10. Serrone L, Zeuli M, Sega FM, Cognetti F. Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview. J Exp Clin Cancer Res 2000; 19:21-34.
11. Atkins JH, Gershell LJ. Selective anticancer drugs. Nat Rev Drug Disc 2002;1:491-2.
12. Stahl JM, Cheung M, Sharma A, Trivedi NR, Shanmugam S, Robertson GP. Loss of PTEN promotes tumor development in malignant melanoma. Cancer Res 2003;63:2891-7.
13. Brazil DP, Park J, Hemmings BA. PKB binding proteins: getting in on the Akt. Cell 2002;111:293-303.
14. Nicholson KM, Anderson NG. The protein kinase B/Akt signalling pathway in human malignancy. Cell Signalling 2002;14:381-95.
15. Chen WS, Xu PZ, Gottlob K, et al. Growth retardation and increased apoptosis in mice with homozygous disruption of the Akt1 gene. Genes Dev 2001;15:2203-8.
16. Cho H, Mu J, Kim JK, et al. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB β). Science 2001;292:1728-31.
17. Cho H, Thorvaldsen JL, Chu Q, Feng F, Birnbaum MJ. Akt1/PKBα is required for normal growth but dispensable for maintenance of glucose homeostasis in mice. J Biol Chem 2001;276:38349-52.
18. Peng XD, Xu PZ, Chen ML, et al. Dwarfism, impaired skin development, skeletal muscle atrophy, delayed bone development and impeded adipogenesis in mice lacking Akt1 and Akt2. Genes Dev 2003;17:1352-65.
19. Staal SP. Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma. Proc Natl Acad Sci USA 1987;84:5034-7.
20. Cheng JQ, Godwin AK, Bellacosa A, et al. AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. Proc Natl Acad Sci USA 1992;89:9267-71.
21. Cheng JQ, Ruggeri B, Klein WM, et al. Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc Natl Acad Sci USA 1996;93:3636-41.
22. Lu Y, Li Z, Sun M. Multiple gene alterations involved in the processor of human gastric carcinogenesis. Chung-Hua i Hsueh Tsa Chih 1995;75:679-82.
23. Bellacosa A, de Feo D, Godwin AK, et al. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int J Cancer 1995;64:280-5.
24. van Dekken H, Geelen E, Dinjens WN, et al. Comparative genomic hybridization of cancer of the gastroesophageal junction: deletion of 14Q31-32.1 discriminates between esophageal (Barrett's) and gastric cardia adenocarcinomas. Cancer Res 1999;59:748-52.
25. Waldmann V, Wacker J, Deichmann M. Mutations of the activation-associated phosphorylation sites at codons 308 and 473 of protein kinase B are absent in human melanoma. Arch Dermatol Res 2001;293:368-72.
26. Waldmann V, Wacker J, Deichmann M. Absence of mutations in the pleckstrin homology (PH) domain of protein kinase B (PKB/Akt) in malignant melanoma. Melanoma Res 2002;12:45-50.
27. Krasilnikov M, Adler V, Fuchs SY, et al. Contribution of phosphatidylinositol 3-kinase to radiation resistance in human melanoma cells. Mol Carcinog 1999;24:64-9.
28. Dhawan P, Singh AB, Ellis DL, Richmond A. Constitutive activation of Akt/protein kinase B in melanoma leads to up-regulation of nuclear factor-κB and tumor progression. Cancer Res 2002;62:7335-42.
29. Sun M, Wang G, Paciga JE, et al. AKT1/PKBα kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells. Am J Pathol 2001;159:431-7.
30. Mitsuuchi Y, Johnson SW, Moonblatt S, Testa JR. Translocation and activation of AKT2 in response to stimulation by insulin. J Cell Biochem 1998;70:433-41.
31. Brodbeck D, Cron P, Hemmings BA. A human protein kinase Bγ with regulatory phosphorylation sites in the activation loop and in the C-terminal hydrophobic domain. J Biol Chem 1999;274:9133-6.
32. Hsu M-Y, Elder DE, Herlyn M. Melanoma: the Wistar (WM) cell lines. In: Masters JRW, Palsson B, editors. Human cell culture, vol. I. London, Great Britain: Kluwer Academic Publishers; 1999. p. 259-74.
33. Herlyn M. Molecular and cellular biology of melanoma. Austin, TX: R.G. Landes Co.; 1993. p. 21-43.
34. Bastian BC, LeBoit PE, Hamm H, Brocker EB, Pinkel D. Chromosomal gains and losses in primary cutaneous melanomas detected by comparative genomic hybridization. Cancer Res 1998;58:2170-5.
35. Thompson FH, Emerson J, Olson S, et al. Cytogenetics of 158 patients with regional or disseminated melanoma: subset analysis of near-diploid and simple karyotypes. Cancer Genet Cytogenet 1995;83:93-104.
36. Mertens F, Johansson B, Höglund M, Mitelman F. Chromosomal imbalance maps of malignant solid tumors: a cytogenetic survey of 3185 neoplasms. Cancer Res 1997; 57:2765-80.
37. Robertson GP, Herbst RA, Nagane M, Huang HJ, Cavenee WK. The chromosome 10 monosomy common in human melanomas results from loss of two separate tumor suppressor loci. Cancer Res 1999;59:3596-601.
38. Parmiter AH, Balaban G, Clark WH Jr, Nowell PC. Possible involvement of the chromosome region 10q24-q26 in early stages of melanocytic neoplasia. Cancer Genet Cytogenet 1988;30:313-7.
39. Powell DJ, Hajduch E, Kular G, Hundal HS. Ceramide disables 3-phosphoinoside binding to the pleckstrin homology domain of protein kinase B (PKB)/Akt by a PKCζ-dependent mechanism. Mol Cell Biol 2003;23:7794-808.
40. Laine J, Kunstle G, Obata T, Noguchi M. Differential regulation of Akt kinase isoforms by the members of the TCL1 oncogene family. J Biol Chem 2002;277:3743-51.
41. Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: a link between cancer genetics and chemotherapy. Cell 2002;108:153-64.